ID

34540

Descrizione

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

collegamento

https://clinicaltrials.gov/show/NCT02468284

Keywords

  1. 19/01/19 19/01/19 -
  2. 22/05/19 22/05/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

19 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Prostate Cancer NCT02468284

Eligibility Prostate Cancer NCT02468284

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Descrizione

ID.1

Tipo di dati

boolean

has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
Descrizione

ID.2

Tipo di dati

boolean

has a screening serum testosterone level >150 ng/dl
Descrizione

ID.3

Tipo di dati

boolean

has an eastern cooperative oncology group (ecog) score of ≤2
Descrizione

ID.4

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Descrizione

ID.5

Tipo di dati

boolean

is currently treated with a 5-alpha reductase inhibitor
Descrizione

ID.6

Tipo di dati

boolean

is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Descrizione

ID.7

Tipo di dati

boolean

is in need of neoadjuvant hormonal therapy
Descrizione

ID.8

Tipo di dati

boolean

has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Prostate Cancer NCT02468284

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial